Acknowledgment
ǂClinical Investigators: Other members of the SentiNot Trialists’ Group are: Imad Mohammed (Department of Surgery, Kalmar County Hospital, Kalmar, Sweden), Abdi Fatah Hersi (Centre for Clinical Research, Uppsala University, Västerås, Sweden), Allan Jazrawi (Centre for Clinical Research, Uppsala University, Västerås, Sweden), Helena Olofsson (Department for Clinical Pathology, Västmanland County Hospital) Peter Stålberg (Department of Surgical Sciences, Uppsala University, Uppsala, Sweden).
Funding
The study was funded by Uppsala University, Uppsala University Hospital, and the Swedish Association for Breast Cancer (Bröstcancerförbundet).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Disclosure
Roger Olofsson Bagge has received institutional research grants from Bristol-Myers Squibb (BMS) and SkyLineDx and speaker honorarium from Roche and Pfizer. He has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche, and Sanofi Genzyme. The remaining authors have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Karakatsanis, A., Eriksson, S., Pistiolis, L. et al. ASO Visual Abstract: Delayed Sentinel Lymph Node Dissection in Patients with a Preoperative Diagnosis of Ductal Cancer In Situ by Preoperative Injection with Superparamagnetic Iron Oxide (SPIO) Nanoparticles: The SentiNot Study. Ann Surg Oncol 30, 4073–4074 (2023). https://doi.org/10.1245/s10434-023-13163-6
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-023-13163-6